吉西他滨联合奥沙利铂治疗进展期胰腺癌

Gemcitabine and Oxaliplatin in Treatment of Advanced Pancreatic Cancer

目的：本研究观察了吉西他滨（健择）联合奥沙利铂（艾恒）组成GO方案治疗进展期胰腺癌的有效性及安全性。方法：自2004年1月-2006年1月,30例进展期胰腺癌患者接受GO方案治疗。GO方案：健择800mg/m^2,静脉滴入第1,第8天,艾恒60 mg/m^2第2第9天,28天为1个周期,共进行6周期,所有患者均接受了至少2个周期的治疗。结果：30例患者平均年龄62岁,所有患者共进行了99周期治疗,平均每个患者接受3.3周期治疗。30例患者中PR 6例,SD11例,PD13例,总有效率为20%,TCR为56.7%。中位进展时间4.37个月,中位生存时间7.14个月,一年生存率为20%。临床受益率显著,CBR达73.3%。具有较好的耐受性,主要毒副反应是血液学毒性。结论：健择联合艾恒治疗进展期胰腺癌疗效较好,毒副反应可以耐受。

Objective：In the present phase Ⅱ multicenter study,we assessed the efficacy and tolerability of the combination of gemcitabine and oxaliplatin in patients with advanced pancreatic cancer.Methods：Patients with previously untreated,locally advanced or metastatic pancreatic cancer were treated with gemcitabine 800 mg/m^2 on days 1 and 8 and oxaliplatin 60 mg/m^2 on day 2 and 9 of a 4-week cycle,for a total of six cycles.All patients received over two cycles of this regimen.Results：A total of 30 patients were enrolled in the study.The median age was 62 years（range 35-72）.A total of 98 cycles were administered.Mean cycle number per patient was 3.3.Among 30 patients evaluable for response,6（20%）achieved partial response;11（36.7%）and 13（43.3%）patients had stable and progressive disease,respectively.The median overall survival was 7.14 months;the median TTP was 4.37 months and the 1-year survival was 20%.The observed clinical benefit response was remarkable.The most common grade 3-4 toxicities were hematological,including 3% anemia,13% neutropenia and 12% thrombocytopenia.Conclusions：The combination of gemcitabine plus oxaliplatin is a moderately active treatment for patients with locally advanced and metastatic pancreatic cancer.This regimen has an acceptable toxicity profile and provides a significant clinical benefit,and hence warrants further investigation.